Tandem (TNDM) Insider File: 406 RSUs Vest; 207 Shares Disposed
Rhea-AI Filing Summary
Rick A. Carpenter, Chief Technology Officer of Tandem Diabetes Care, reported transactions on 09/15/2025 affecting his holdings of TNDM common stock. 406 restricted stock units (RSUs) vested and were recorded as acquired under code M with a $0 price, leaving 22,773 shares beneficially owned after the transaction. Separately, 207 shares were disposed of under code F(1) at $12.09 per share, leaving 22,566 shares reported as beneficially owned following that disposition. The filing states that the Company withheld shares to satisfy tax withholding on RSU vesting and that no shares were sold to cover taxes. The RSUs were originally awarded on 12/15/2021 under the 2013 Stock Incentive Plan and vest 25% on 12/15/2022 with the remainder vesting in twelve equal quarterly installments.
Positive
- RSU vesting recorded (406 RSUs) indicating routine compensation rather than opportunistic selling
- Tax withholding via share retention rather than open-market sales, as disclosed in the filing
Negative
- Disposition of 207 shares at $12.09 reduced reported beneficial ownership modestly
Insights
TL;DR: Insider received RSU vesting and a small disposition; overall ownership change is immaterial to company valuation.
The report documents routine compensation-related activity: vesting of 406 RSUs and a related disposition of 207 shares at $12.09 per share, with share withholding used to satisfy taxes rather than a cash sale. The net change in reported beneficial ownership is modest (from documented figures), and there is no indication of large-scale selling pressure or material dilution beyond standard employee compensation mechanics. For investors, this is a standard insider compensation event rather than a signal of operational or financial change.
TL;DR: Disclosure aligns with Section 16 reporting rules and internal compensation plans; documentation is complete.
The Form 4 clearly identifies the reporting person, relationship (Chief Technology Officer), transaction dates, codes (M for RSU vesting and F(1) for disposition), and explains tax-withholding treatment. The filing references the 2013 Stock Incentive Plan and the original award date (12/15/2021), and includes vesting schedule language. The signature is provided by an attorney-in-fact, meeting procedural requirements. There are no governance red flags or missing required disclosures in the provided content.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 406 | $0.00 | -- |
| Exercise | Common Stock | 406 | $0.00 | -- |
| Tax Withholding | Common Stock | 207 | $12.09 | $3K |
Footnotes (1)
- Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Awarded on December 15, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 12/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.
